Home
ABOUT US
Overview
Business Model
Board of Directors
Management Team
History & Milestones
Corporate Social Responsibility
R & D PIPELINE
INVESTORS
Investor Overview
Financial Reports
Shareholders’ Meetings
Events & Presentations
NEWS
CAREERS
CONTACT
EN
中文版
NEW DRUGS FOR THE TREATMENT OF CANCER
PharmaEngine
We Race With You
DISCOVER MORE
CANCER TREATMENT PRODUCTS
ONIVYDE
A Revolutionary Durg
DISCOVER ONIVYDE
NEW CONCEPTS FOR RADIOTHERAPY
Groundbreaking
Cancer Treatment
DISCOVER PEP503
History
&
Milestones
Onivyde
PharmaEngine and Nanobiotix to Terminate Asia-Pacific Exclusive License and Collaboration Agreement for NBTXR3
2021/3/5
PharmaEngine, Inc. Announces First Results for PEP503(NBTXR3) in Rectal Cancer Study at ASCO-GI 2021
2021/1/15
PharmaEngine, Inc. and Sentinel Oncology Limited Enter into an Exclusive Collaboration and License Agreement for SOL-578, a Chk1 inhibitor
2020/11/26
PEP503
R&D Pipeline
Events & Presentations
Organization
Our Partners
Contact Us
Go To Top